首页 > 最新文献

European Journal of Internal Medicine最新文献

英文 中文
Triglyceride glucose (TyG) index: A promising biomarker for diagnosis and treatment of different diseases 甘油三酯葡萄糖（TyG）指数：用于诊断和治疗不同疾病的有前途的生物标志物。
IF 5.9 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL
European Journal of Internal Medicine
Pub Date : 2025-01-01 DOI: 10.1016/j.ejim.2024.08.026
Yuting Sun , Hangyu Ji , Wenjie Sun , Xuedong An, Fengmei Lian
The Triglyceride-glucose index (TyG index) is a comprehensive statistical measure that incorporates fasting triglyceride and fasting glucose levels. Research has demonstrated that it can serve as an effective alternative biomarker for insulin resistance (IR) due to its high sensitivity and specificity. The TyG index is straightforward to compute and imposes fewer time and cost constraints, rendering it suitable for large populations and advantageous for use in various applications, clinical settings, and epidemiological investigations. Numerous high-quality clinical studies have underscored the significance of the TyG index in diverse medical conditions. This review provides a synthesis of the association between the TyG index and diseases such as diabetes, cardiovascular diseases, cerebrovascular diseases, fatty liver, kidney diseases, and reproductive system diseases. Furthermore, the TyG index has exhibited predictive capabilities for identifying IR in children and adolescents. Through a systematic review of pertinent clinical trials, this paper elucidates the correlation between the TyG index and various diseases. The findings presented herein suggest that the TyG index holds promise as a valuable and practical indicator for different medical conditions, prompting a reevaluation of conventional disease risk assessment paradigms and highlighting the intricate interplay of metabolic parameters with diverse diseases. By leveraging insights from the TyG index, tailored disease risk management strategies can be developed to offer a fresh perspective and guidance for clinical interventions.
甘油三酯-葡萄糖指数（TyG 指数）是一种综合统计测量方法，包含空腹甘油三酯和空腹葡萄糖水平。研究表明，由于其灵敏度和特异性较高，它可以作为胰岛素抵抗（IR）的有效替代生物标志物。TyG 指数计算简便，时间和成本限制较少，适用于大量人群，在各种应用、临床环境和流行病学调查中具有优势。大量高质量的临床研究强调了TyG指数在各种医疗状况中的重要性。本综述综述了TyG指数与糖尿病、心血管疾病、脑血管疾病、脂肪肝、肾脏疾病和生殖系统疾病等疾病之间的关系。此外，TyG指数还显示出了识别儿童和青少年红外的预测能力。本文通过对相关临床试验的系统回顾，阐明了 TyG 指数与各种疾病之间的相关性。本文的研究结果表明，TyG 指数有望成为不同病症的有价值的实用指标，促使人们重新评估传统的疾病风险评估范式，并强调了代谢参数与不同疾病之间错综复杂的相互作用。通过利用TyG指数的洞察力，可以制定量身定制的疾病风险管理战略，为临床干预提供全新的视角和指导。
{"title":"Triglyceride glucose (TyG) index: A promising biomarker for diagnosis and treatment of different diseases","authors":"Yuting Sun ,&nbsp;Hangyu Ji ,&nbsp;Wenjie Sun ,&nbsp;Xuedong An,&nbsp;Fengmei Lian","doi":"10.1016/j.ejim.2024.08.026","DOIUrl":"10.1016/j.ejim.2024.08.026","url":null,"abstract":"<div><div>The Triglyceride-glucose index (TyG index) is a comprehensive statistical measure that incorporates fasting triglyceride and fasting glucose levels. Research has demonstrated that it can serve as an effective alternative biomarker for insulin resistance (IR) due to its high sensitivity and specificity. The TyG index is straightforward to compute and imposes fewer time and cost constraints, rendering it suitable for large populations and advantageous for use in various applications, clinical settings, and epidemiological investigations. Numerous high-quality clinical studies have underscored the significance of the TyG index in diverse medical conditions. This review provides a synthesis of the association between the TyG index and diseases such as diabetes, cardiovascular diseases, cerebrovascular diseases, fatty liver, kidney diseases, and reproductive system diseases. Furthermore, the TyG index has exhibited predictive capabilities for identifying IR in children and adolescents. Through a systematic review of pertinent clinical trials, this paper elucidates the correlation between the TyG index and various diseases. The findings presented herein suggest that the TyG index holds promise as a valuable and practical indicator for different medical conditions, prompting a reevaluation of conventional disease risk assessment paradigms and highlighting the intricate interplay of metabolic parameters with diverse diseases. By leveraging insights from the TyG index, tailored disease risk management strategies can be developed to offer a fresh perspective and guidance for clinical interventions.</div></div>","PeriodicalId":50485,"journal":{"name":"European Journal of Internal Medicine","volume":"131 ","pages":"Pages 3-14"},"PeriodicalIF":5.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142607428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A new era in optimization of anti-infective therapy: Current challenges and priorities 优化抗感染治疗的新时代：当前的挑战和优先事项。
IF 5.9 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL
European Journal of Internal Medicine
Pub Date : 2025-01-01 DOI: 10.1016/j.ejim.2024.11.009
Jordi Rello , Virginie Prendki , Grant W. Waterer
{"title":"A new era in optimization of anti-infective therapy: Current challenges and priorities","authors":"Jordi Rello ,&nbsp;Virginie Prendki ,&nbsp;Grant W. Waterer","doi":"10.1016/j.ejim.2024.11.009","DOIUrl":"10.1016/j.ejim.2024.11.009","url":null,"abstract":"","PeriodicalId":50485,"journal":{"name":"European Journal of Internal Medicine","volume":"131 ","pages":"Pages 36-37"},"PeriodicalIF":5.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142710242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Coronary artery pulsatile ectasia and multiple occlusion in an adolescent male 青少年男性冠状动脉搏动性扩张和多发闭塞。
IF 5.9 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL
European Journal of Internal Medicine
Pub Date : 2025-01-01 DOI: 10.1016/j.ejim.2024.11.026
Junwen Wang , Xuefeng Chen , Yong Peng
{"title":"Coronary artery pulsatile ectasia and multiple occlusion in an adolescent male","authors":"Junwen Wang ,&nbsp;Xuefeng Chen ,&nbsp;Yong Peng","doi":"10.1016/j.ejim.2024.11.026","DOIUrl":"10.1016/j.ejim.2024.11.026","url":null,"abstract":"","PeriodicalId":50485,"journal":{"name":"European Journal of Internal Medicine","volume":"131 ","pages":"Pages 135-137"},"PeriodicalIF":5.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142774504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adherence to the 2019 ESC/EAS guidelines for dyslipidaemia management in a large rheumatoid arthritis cohort: Data from the CORDIS Study Group of the Italian Society of Rheumatology 大型类风湿性关节炎队列中对 2019 ESC/EAS 血脂异常管理指南的遵守情况：意大利风湿病学会 CORDIS 研究小组的数据。
IF 5.9 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL
European Journal of Internal Medicine
Pub Date : 2025-01-01 DOI: 10.1016/j.ejim.2024.10.029
Fabio Cacciapaglia , Francesca Romana Spinelli , Gian Luca Erre , Matteo Piga , Garifallia Sakellariou , Andreina Manfredi , Marco Fornaro , Ombretta Viapiana , Simone Perniola , Elisa Gremese , Fabiola Atzeni , Elena Bartoloni

Background/aim

Lipid-lowering therapy prescription is low in rheumatoid arthritis (RA) patients, often not achieving lipid threshold target despite treatment. However, evidence derives from small, monocentric cohorts. We assessed adherence to lipid-lowering treatment for primary cardiovascular (CV) prevention in a RA cohort according to international guidelines.

Methods

A cross-sectional analysis of an Italian RA cohort was performed. Disease-related features and traditional CV risk factors were collected. The 10-year CV risk was estimated by Systematic COronary Risk Evaluation 2 (SCORE-2) algorithm. The primary preventive dyslipidaemia strategy was assessed according to 2019 European Society of Cardiology/European Atherosclerosis Society guidelines.

Results

1.133 RA patients (78.2% female, aged 60.6±10.2 years) free from CV events were included. According to SCORE-2, 42.9% of patients were at moderate risk (1–5-%), 33.3% at high risk (5–10%) and 23.7% at very high risk (>10%). In the whole cohort, 12.9% of patients with <5%, 23.6% with 5–10% and 32.3% with >10% risk were on statin, respectively (p<0.001). According to 2019 ESC/EAS guidelines, 51.5% of patients had LDL-c at target. Among patients with LDL-c not at target, 76% were not on lipid-lowering treatment. At multivariate analysis, patients with higher CV risk had significantly lower probability of LDL-c at target.

Conclusion

In a wide Italian RA cohort, more than 50% of patients had high or very high CV risk. In these, lipid-lowering treatment prescription is suboptimal leading to not achievement of LDL-c target. Physicians should improve lipid screening and primary prevention therapy to reduce CV risk and improve CV comorbidity in RA patients.
背景/目的：类风湿性关节炎（RA）患者的降脂治疗处方量较低，尽管接受了治疗，但往往达不到血脂阈值目标。然而，这些证据均来自小型、单一的队列。我们根据国际指南评估了RA队列中坚持降脂治疗以进行心血管（CV）一级预防的情况：我们对一个意大利 RA 队列进行了横断面分析。收集了疾病相关特征和传统的心血管风险因素。通过系统性冠状动脉风险评估 2（SCORE-2）算法估算了 10 年的冠状动脉风险。根据2019年欧洲心脏病学会/欧洲动脉粥样硬化学会指南评估了一级预防血脂异常策略：共纳入 1.133 名未发生过心血管事件的 RA 患者（78.2% 为女性，年龄为 60.6±10.2 岁）。根据SCORE-2，42.9%的患者为中度风险（1-5-%），33.3%为高度风险（5-10%），23.7%为非常高度风险（>10%）。在整个队列中，10%风险的患者中分别有12.9%在服用他汀类药物（P结论：在一个广泛的意大利 RA 队列中，50% 以上的患者有较高或极高的心血管疾病风险。在这些患者中，降脂治疗处方并不理想，导致无法实现低密度脂蛋白胆固醇目标。医生应改善血脂筛查和一级预防治疗，以降低心血管风险并改善 RA 患者的心血管并发症。
{"title":"Adherence to the 2019 ESC/EAS guidelines for dyslipidaemia management in a large rheumatoid arthritis cohort: Data from the CORDIS Study Group of the Italian Society of Rheumatology","authors":"Fabio Cacciapaglia ,&nbsp;Francesca Romana Spinelli ,&nbsp;Gian Luca Erre ,&nbsp;Matteo Piga ,&nbsp;Garifallia Sakellariou ,&nbsp;Andreina Manfredi ,&nbsp;Marco Fornaro ,&nbsp;Ombretta Viapiana ,&nbsp;Simone Perniola ,&nbsp;Elisa Gremese ,&nbsp;Fabiola Atzeni ,&nbsp;Elena Bartoloni","doi":"10.1016/j.ejim.2024.10.029","DOIUrl":"10.1016/j.ejim.2024.10.029","url":null,"abstract":"<div><h3>Background/aim</h3><div>Lipid-lowering therapy prescription is low in rheumatoid arthritis (RA) patients, often not achieving lipid threshold target despite treatment. However, evidence derives from small, monocentric cohorts. We assessed adherence to lipid-lowering treatment for primary cardiovascular (CV) prevention in a RA cohort according to international guidelines.</div></div><div><h3>Methods</h3><div>A cross-sectional analysis of an Italian RA cohort was performed. Disease-related features and traditional CV risk factors were collected. The 10-year CV risk was estimated by Systematic COronary Risk Evaluation 2 (SCORE-2) algorithm. The primary preventive dyslipidaemia strategy was assessed according to 2019 European Society of Cardiology/European Atherosclerosis Society guidelines.</div></div><div><h3>Results</h3><div>1.133 RA patients (78.2% female, aged 60.6±10.2 years) free from CV events were included. According to SCORE-2, 42.9% of patients were at moderate risk (1–5-%), 33.3% at high risk (5–10%) and 23.7% at very high risk (&gt;10%). In the whole cohort, 12.9% of patients with &lt;5%, 23.6% with 5–10% and 32.3% with &gt;10% risk were on statin, respectively (<em>p</em>&lt;0.001). According to 2019 ESC/EAS guidelines, 51.5% of patients had LDL-c at target. Among patients with LDL-c not at target, 76% were not on lipid-lowering treatment. At multivariate analysis, patients with higher CV risk had significantly lower probability of LDL-c at target.</div></div><div><h3>Conclusion</h3><div>In a wide Italian RA cohort, more than 50% of patients had high or very high CV risk. In these, lipid-lowering treatment prescription is suboptimal leading to not achievement of LDL-c target. Physicians should improve lipid screening and primary prevention therapy to reduce CV risk and improve CV comorbidity in RA patients.</div></div>","PeriodicalId":50485,"journal":{"name":"European Journal of Internal Medicine","volume":"131 ","pages":"Pages 98-103"},"PeriodicalIF":5.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142583538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enhancing immunization strategies in heart failure: A call to action 加强心力衰竭的免疫策略：行动呼吁。
IF 5.9 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL
European Journal of Internal Medicine
Pub Date : 2025-01-01 DOI: 10.1016/j.ejim.2024.08.021
José Guilherme Assis
{"title":"Enhancing immunization strategies in heart failure: A call to action","authors":"José Guilherme Assis","doi":"10.1016/j.ejim.2024.08.021","DOIUrl":"10.1016/j.ejim.2024.08.021","url":null,"abstract":"","PeriodicalId":50485,"journal":{"name":"European Journal of Internal Medicine","volume":"131 ","pages":"Pages 153-154"},"PeriodicalIF":5.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142114419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative safety and efficacy analysis of GLP-1 receptor agonists and SGLT-2 inhibitors among frail individuals with type 2 diabetes in the era of continuous population ageing 在人口持续老龄化的时代，GLP-1 受体激动剂和 SGLT-2 抑制剂在体弱的 2 型糖尿病患者中的安全性和疗效比较分析。
IF 5.9 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL
European Journal of Internal Medicine
Pub Date : 2025-01-01 DOI: 10.1016/j.ejim.2024.09.020
Paschalis Karakasis , Dimitrios Patoulias , Ieva Ruža , Alberto Maria Marra , Ricardo Gómez-Huelgas
{"title":"Comparative safety and efficacy analysis of GLP-1 receptor agonists and SGLT-2 inhibitors among frail individuals with type 2 diabetes in the era of continuous population ageing","authors":"Paschalis Karakasis ,&nbsp;Dimitrios Patoulias ,&nbsp;Ieva Ruža ,&nbsp;Alberto Maria Marra ,&nbsp;Ricardo Gómez-Huelgas","doi":"10.1016/j.ejim.2024.09.020","DOIUrl":"10.1016/j.ejim.2024.09.020","url":null,"abstract":"","PeriodicalId":50485,"journal":{"name":"European Journal of Internal Medicine","volume":"131 ","pages":"Pages 162-165"},"PeriodicalIF":5.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142373452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Precision medicine in COPD: A possible contribution of vitamin D? 慢性阻塞性肺病的精准医疗：维生素 D 的可能贡献？
IF 5.9 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL
European Journal of Internal Medicine
Pub Date : 2025-01-01 DOI: 10.1016/j.ejim.2024.07.020
Gianluca Azzellino , Lia Ginaldi , Massimo De Martinis
{"title":"Precision medicine in COPD: A possible contribution of vitamin D?","authors":"Gianluca Azzellino ,&nbsp;Lia Ginaldi ,&nbsp;Massimo De Martinis","doi":"10.1016/j.ejim.2024.07.020","DOIUrl":"10.1016/j.ejim.2024.07.020","url":null,"abstract":"","PeriodicalId":50485,"journal":{"name":"European Journal of Internal Medicine","volume":"131 ","pages":"Pages 143-144"},"PeriodicalIF":5.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141753304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The new ESC 2024 guidelines on the management of peripheral arterial and aortic diseases: Lights and shadows 新版ESC 2024外周动脉和主动脉疾病管理指南：光与影。
IF 5.9 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL
European Journal of Internal Medicine
Pub Date : 2025-01-01 DOI: 10.1016/j.ejim.2024.10.025
Claudio Cimminiello , Mauro Molteni
{"title":"The new ESC 2024 guidelines on the management of peripheral arterial and aortic diseases: Lights and shadows","authors":"Claudio Cimminiello ,&nbsp;Mauro Molteni","doi":"10.1016/j.ejim.2024.10.025","DOIUrl":"10.1016/j.ejim.2024.10.025","url":null,"abstract":"","PeriodicalId":50485,"journal":{"name":"European Journal of Internal Medicine","volume":"131 ","pages":"Pages 1-2"},"PeriodicalIF":5.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142583539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The prediction of alterations in plasma sodium levels in acutely ill patients should be more comprehensive 对急症患者血浆钠水平变化的预测应该更加全面。
IF 5.9 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL
European Journal of Internal Medicine
Pub Date : 2025-01-01 DOI: 10.1016/j.ejim.2024.08.013
Milosz J. Jaguszewski , Michal Pruc , Lukasz Szarpak
{"title":"The prediction of alterations in plasma sodium levels in acutely ill patients should be more comprehensive","authors":"Milosz J. Jaguszewski ,&nbsp;Michal Pruc ,&nbsp;Lukasz Szarpak","doi":"10.1016/j.ejim.2024.08.013","DOIUrl":"10.1016/j.ejim.2024.08.013","url":null,"abstract":"","PeriodicalId":50485,"journal":{"name":"European Journal of Internal Medicine","volume":"131 ","pages":"Pages 148-149"},"PeriodicalIF":5.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141996862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The prediction of alterations in plasma sodium levels in acutely ill patients should be more comprehensive. Author's reply 对急症患者血浆钠水平变化的预测应更加全面。作者回复。
IF 5.9 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL
European Journal of Internal Medicine
Pub Date : 2025-01-01 DOI: 10.1016/j.ejim.2024.09.010
S.S.A. Simon , A.M.C. van Vliet , L. Vogt , G. Lindner , R.H.G. Olde Engberink
{"title":"The prediction of alterations in plasma sodium levels in acutely ill patients should be more comprehensive. Author's reply","authors":"S.S.A. Simon ,&nbsp;A.M.C. van Vliet ,&nbsp;L. Vogt ,&nbsp;G. Lindner ,&nbsp;R.H.G. Olde Engberink","doi":"10.1016/j.ejim.2024.09.010","DOIUrl":"10.1016/j.ejim.2024.09.010","url":null,"abstract":"","PeriodicalId":50485,"journal":{"name":"European Journal of Internal Medicine","volume":"131 ","pages":"Page 158"},"PeriodicalIF":5.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142300022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页
类型
全部 化学•材料 生命科学 医学 物理 工程技术 环境•农林 材料科学 地球科学 法学 管理学 化学 环境科学与生态学 计算机科学 教育学 经济学 农林科学 人文科学 生物学 数学 物理与天体物理 心理学 综合性期刊 其他 工业工程 理学 历史学 农学 文学 信息工程
数据库
全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley
期刊
European Journal of Internal Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
﹀
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们：info@booksci.cn
Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1